Download PDF
CC BY-NC-ND 4.0 · Sleep Sci 2017; 10(01): 11-18
DOI: 10.5935/1984-0063.20170003
ORIGINAL ARTICLE

Sleep, Melatonin, and the Menopausal Transition: What Are the Links?

Shazia Jehan
1   Center for Healthful Behavior Change, New York University School of Medicine, New York, USA
,
Giardin Jean-Louis
1   Center for Healthful Behavior Change, New York University School of Medicine, New York, USA
,
Ferdinand Zizi
1   Center for Healthful Behavior Change, New York University School of Medicine, New York, USA
,
Evan Auguste
1   Center for Healthful Behavior Change, New York University School of Medicine, New York, USA
,
Seitikurippu R. Pandi-Perumal
2   Somnogen Canada Inc., College Street, Toronto, ON M6H 1C5, CANADA.
,
Ravi Gupta
3   Department of Psychiatry & Sleep Clinic, Himalayan Institute of Medical Sciences, Swami Ram Nagar, Jolly Grant, Dehradun-248016, INDIA.
,
Hrayr Attarian
4   Circadian Rhythms and Sleep Research Lab, Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
,
Samy I. McFarlane
5   Division of Endocrinology, Department of Medicine, SUNY Downstate Medical Center, 11203 Brooklyn, NY, USA.
,
Rüdiger Hardeland
6   Johann Friedrich Blumenbach Institute of Zoology and Anthropology, University of Göttingen, D-37073 Göttingen, Germany.
,
Amnon Brzezinski
7   Department of Obstetrics & Gynecology, the Hebrew University-Hadassah Medical Center, Jerusalem, Israel
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

The pineal hormone Melatonin plays an important role in the regulation of the circadian sleep/wake cycle, mood, and perhaps immune functions, carcinogensis and reproduction. The human circadian rhythm of melatonin release from the pineal gland is tightly synchronized with the habitual hours of sleep. Peri- and postmenopausal women often complain of difficulties initiating and/or maintaining sleep, with frequent nocturnal and early morning awakenings. In this review we discuss the pathophysiology of melatonin function as it relates to sleep disorders in menopausal women, highlighting the potential use of exogenous melatonin during the menopausal transition and beyond.

Sleep - Melatonin - Aging - Circadian rhythm - Hormones - Gender - Menopause

Disclosure Statement

The authors have read the journal's policy and have the following potential conflicts: This study was not an industry-supported study. S.R. Pandi-Perumal is a stockholder and the President and Chief Executive Officer of Somnogen Canada Inc., a Canadian Corporation. This does not alter his adherence to all the journal policies. He declares that he has no competing interests that might be perceived to influence the content of this article. All remaining authors declare that they have no proprietary, financial, professional, nor any other personal interest of any nature or kind in any product or services and/or company that could be construed or considered to be a potential conflict of interest that might have influenced the views expressed in this manuscript.




Publication History

Received: 15 August 2016

Accepted: 28 December 2016

Article published online:
29 September 2023

© 2023. Brazilian Sleep Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • REFERENCES

  • 1 Jehan S, Masters-Isarilov A, Salifu I, Zizi F, Jean-Louis G, Pandi-Perumal SR, et al. Sleep Disorders in Postmenopausal Women. J Sleep Disord Ther. 2015;4(5). pii: 1000212.
  • 2 Carranza-Lira S, García López F. Melatonin and climactery. Med Sci Monit. 2000;6(6):1209-12.
  • 3 Marcolina ST, Rosenshein B. Insomnia in Women: Menopause and Melatonin Part III of III-Part Series. 2008 [cited 2017 Mar 24. Available from: https://www.ahcmedia.com/articles/13301-insomnia-in-women-menopause-and-melatonin
  • 4 Eichling PS, Sahni J. Menopause related sleep disorders. J Clin Sleep Med. 2005;1(3):291-300.
  • 5 Hardeland R. Melatonin in aging and disease-multiple consequences of reduced secretion, options and limits of treatment. Aging Dis. 2012;3(2):194-225.
  • 6 Mistlberger RE. Circadian regulation of sleep in mammals: role of the suprachiasmatic nucleus. Brain Res Brain Res Rev. 2005;49(3):429-54.
  • 7 Moore RY. Suprachiasmatic nucleus in sleep-wake regulation. Sleep Med. 2007;8 Suppl 3:27-33.
  • 8 Moore RY. The suprachiasmatic nucleus and the circadian timing system. Prog Mol Biol Transl Sci. 2013;119:1-28.
  • 9 Hardeland R. Melatonin, hormone of darkness and more: occurrence, control mechanisms, actions and bioactive metabolites. Cel Mol Life Sci. 2008;65(13):2001-18.
  • 10 Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in humans. Science. 1980;210(4475):1267-9.
  • 11 Brown GM. Light, melatonin and the sleep-wake cycle. J Psychiatry Neurosci. 1994;19(5):345-53.
  • 12 Duffy JF, Czeisler CA. Effect of light on human circadian physiology. Sleep Med Clin. 2009;4(2):165-77.
  • 13 Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia. 1993;49(8):654-64.
  • 14 Wahnschaffe A, Haedel S, Rodenbeck A, Stoll C, Rudolph H, Kozakov R, et al. Out of the lab and into the bathroom: evening short-term exposure to conventional light suppresses melatonin and increases alertness perception. Int J Mol Sci. 2013;14(2):2573-89.
  • 15 Klein DC. Arylalkylamine N-acetyltransferase: “the Timezyme”. J Biol Chem. 2007;282(7):4233-7.
  • 16 Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: Nature’s most versatile biological signal? FEBS J. 2006;273(13):2813-38.
  • 17 Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin--a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2011;93(3):350-84.
  • 18 Reiter RJ, Tan DX, Kim SJ, Cruz MH. Delivery of pineal melatonin to the brain and SCN: role of canaliculi, cerebrospinal fluid, tanycytes and Virchow-Robin perivascular spaces. Brain Struct Funct. 2014;219(6):1873-87.
  • 19 Tan DX, Manchester LC, Reiter RJ. CSF generation by pineal gland results in a robust melatonin circadian rhythm in the third ventricle as an unique light/dark signal. Med Hypotheses. 2016;86:3-9.
  • 20 Pinato L, da Silveira Cruz-Machado S, Franco DG, Campos LM, Cecon E, Fernandes PA, et al. Selective protection of the cerebellum against intracerebroventricular LPS is mediated by local melatonin synthesis. Brain Struct Funct. 2015;220(2):827-40.
  • 21 Acuna-Castroviejo D, Escames G, Venegas C, Diaz-Casado ME, Lima-Cabello E, Lopez LC, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cel Mol Life Sci. 2014;71(16):2997-3025.
  • 22 Hardeland R, Poeggeler B. Melatonin beyond its classical functions. Open Physiol J. 2008;1:1-23.
  • 23 Hardeland R, Madrid JA, Tan DX, Reiter RJ. Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J Pineal Res. 2012;52(2):139-66.
  • 24 Doghramji K. Melatonin and its receptors: a new class of sleep-promoting agents. J Clin Sleep Med. 2007;3(5 Suppl):S17-23.
  • 25 Miller SC, Pandi-Perumal SR, Esquifino AI, Cardinali DP, Maestroni GJ. The role of melatonin in immuno enhancement: potential application in cancer. Int J Exp Pathol. 2006;87(2):81-7.
  • 26 Pandi-Perumal S, Spence DW, Brown GM, Thorpy MJ. Great challenges to sleep medicine: problems and paradigms. Front Neurol. 2010;1:7.
  • 27 Schmidt C, Peigneux P, Leclercq Y, Sterpenich V, Vandewalle G, Phillips C, et al. Circadian preference modulates the neural substrate of conflict processing across the day. PloS One. 2012;7(1):e29658.
  • 28 Hardeland R. Melatonin and the theories of aging: a critical appraisal of melatonin’s role in antiaging mechanisms. J Pineal Res. 2013;55(4):325-56.
  • 29 Hardeland R. Melatonin and Synthetic Melatoninergic Agonists in Pspchiatric and Age-Associated Disorders: Successful and Unsuccessful Approaches. Curr Pharm Des. 2016;22(8):1086-101.
  • 30 Mishima K, Tozawa T, Satoh K, Matsumoto Y, Hishikawa Y, Okawa M. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer’s type with disturbed sleep-waking. Biol Psychiatry. 1999;45(4):417-21.
  • 31 Rohr UD, Herold J. Melatonin deficiencies in women. Maturitas. 2002;41 Suppl 1:85-104.
  • 32 Bortolato B, Berk M, Maes M, McIntyre RS, Carvalho AF. Fibromyalgia and Bipolar Disorder: Emerging Epidemiological Associations and Shared Pathophysiology. Curr Mol Med. 2016;16(2):119-36.
  • 33 Gumral N, Naziroglu M, Ongel K, Beydilli ED, Ozguner F, Sutcu R, et al. Antioxidant enzymes and melatonin levels in patients with bronchial asthma and chronic obstructive pulmonary disease during stable and exacerbation periods. Cell Biochem Funct. 2009;27(5):276-83.
  • 34 Hernandez C, Abreu J, Abreu P, Castro A, Jimenez A. Nocturnal melatonin plasma levels in patients with OSAS: the effect of CPAP. Eur Respir J. 2007;30(3):496-500.
  • 35 Lemmer B, Scholtze J, Schmitt J. Circadian rhythms in blood pressure, heart rate, hormones, and on polysomnographic parameters in severe obstructive sleep apnea syndrome patients: effect of continuous positive airway pressure. Blood Press Monit. 2016;21(3):136-43.
  • 36 Mahdi AA, Fatima G, Das SK, Verma NS. Abnormality of circadian rhythm of serum melatonin and other biochemical parameters in fibromyalgia syndrome. Indian J Biochem Biophys. 2011;48(2):82-7.
  • 37 Pernambuco A, Schetino LP, Viana RS, Carvalho LS, d’Avila Reis D. The involvement of melatonin in the clinical status of patients with fibromyalgia syndrome. Clin Exp Rheumatol. 2015;33(1 Suppl 88):S14-9.
  • 38 Reiter RJ. Melatonin and human reproduction. Ann Med. 1998;30(1):103-8.
  • 39 Gursoy AY, Kiseli M, Caglar GS. Melatonin in aging women. Climacteric. 2015;18(6):790-6.
  • 40 Hardeland R, Cardinali DP, Brown GM, Pandi-Perumal SR. Melatonin and brain inflammaging. Prog Neurobiol. 2015;127-128:46-63.
  • 41 Pandi-Perumal SR, Smits M, Spence W, Srinivasan V, Cardinali DP, Lowe AD, et al. Dim light melatonin onset (DLMO): a tool for the analysis of circadian phase in human sleep and chronobiological disorders. Progr Neuropsychopharmacol Biol Psychiatry. 2007;31(1):1-11.
  • 42 Olbrich D, Dittmar M. Older poor-sleeping women display a smaller evening increase in melatonin secretion and lower values of melatonin and core body temperature than good sleepers. Chronobiol Int. 2011;28(8):681-9.
  • 43 Karasek M. Melatonin, human aging, and age-related diseases. Exp Gerontol. 2004;39(11-12):1723-9.
  • 44 Carrillo-Vico A, Smits M, Spence W, Srinivasan V, Cardinali DP, Lowe AD. Melatonin: buffering the immune system. Int J Mol Sci. 2013;14(4):8638-83.
  • 45 Reiter RJ, Manchester LC, Tan DX. Neurotoxins: free radical mechanisms and melatonin protection. Curr Neuropharmacol. 2010;8(3):194-210.
  • 46 Hardeland R. Melatonin, mitochondrial electron flux and leakage: recent findings and resolution of contradictory results. Adv Stud Biol. 2009;1(5):207-30.
  • 47 Al-Safi ZA, Santoro N. Menopausal hormone therapy and menopausal symptoms. Fertil Steril. 2014;101(4):905-15.
  • 48 Twiss JJ, Wegner J, Hunter M, Kelsay M, Rathe-Hart M, Salado W. Perimenopausal symptoms, quality of life, and health behaviors in users and nonusers of hormone therapy. J Am Acad Nurse Pract. 2007;19(11):602-13.
  • 49 Weber MT, Rubin LH, Maki PM. Cognition in perimenopause: the effect of transition stage. Menopause. 2013;20(5):511-7.
  • 50 Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193-213.
  • 51 Schmidt PJ. Mood, depression, and reproductive hormones in the menopausal transition. Am J Med. 2005;118(12):54-8.
  • 52 Berecki-Gisolf J, Begum N, Dobson AJ. Symptoms reported by women in midlife: menopausal transition or aging? Menopause. 2009;16(5):1021-9.
  • 53 Lassila H, Johns NP, O’Neil CK, Johns JR, Balk JL, Witt-Enderby PA. Alternative Options to Manage Menopausal Symptoms with a Focus on Melatonin and Osteoporosis. Clin Pharmacol Biopharm. 2014;3:115.
  • 54 Kotlarczyk MP, Lassila HC, O’Neil CK, D’Amico F, Enderby LT, Witt-Enderby PA, et al. Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women. J Pineal Res. 2012;52(4):414-26.
  • 55 Viswanathan AN, Schernhammer ES. Circulating melatonin and the risk of breast and endometrial cancer in women. Cancer Lett. 2009;281(1):1-7.
  • 56 Nooshinfar E, Safaroghli-Azar A, Bashash D, Akbari ME. Melatonin, an inhibitory agent in breast cancer. Breast Cancer. 2017;24(1):42-51.
  • 57 Jia Y, Lu Y, Wu K, Lin Q, Shen W, Zhu M, et al. Does night work increase the risk of breast cancer? A systematic review and meta-analysis of epidemiological studies. Cancer Epidemiol. 2013;37(3):197-206.
  • 58 Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine. 2005;27(2):179-88.
  • 59 Hill SM, Frasch T, Xiang S, Yuan L, Duplessis T, Mao L. Molecular mechanisms of melatonin anticancer effects. Integr Cancer Ther. 2009;8(4):337-46.
  • 60 Lee SE, Kim SJ, Youn JP, Hwang SY, Park CS, Park YS. MicroRNA and gene expression analysis of melatonin-exposed human breast cancer cell lines indicating involvement of the anticancer effect. J Pineal Res. 2011;51(3):345-52.
  • 61 Lee SE, Kim SJ, Yoon HJ, Yu SY, Yang H, Jeong SI, et al. Genome-wide profiling in melatonin-exposed human breast cancer cell lines identifies differentially methylated genes involved in the anticancer effect of melatonin. J Pineal Res. 2013;54(1):80-8.
  • 62 Schernhammer ES, Hankinson SE. Urinary melatonin levels and postmenopausal breast cancer risk in the Nurses’ Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2009;18(1):74-9.
  • 63 Carlson LE, Campbell TS, Garland SN, Grossman P. Associations among salivary cortisol, melatonin, catecholamines, sleep quality and stress in women with breast cancer and healthy controls. J Behav Med. 2007;30(1):45-58.
  • 64 Lanoix D, Lacasse AA, Reiter RJ, Vaillancourt C. Melatonin: the smart killer: the human trophoblast as a model. Mol Cell Endocrinol. 2012;348(1):1-11.
  • 65 Bizzarri M, Proietti S, Cucina A, Reiter RJ. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin Ther Targets. 2013;17(12):1483-96.
  • 66 Srinivasan V, Spence DW, Pandi-Perumal SR, Trakht I, Cardinali DP. Therapeutic actions of melatonin in cancer: possible mechanisms. Integr Cancer Ther. 2008;7(3):189-203.
  • 67 Grin W, Grünberger W. A significant correlation between melatonin deficiency and endometrial cancer. Gynecol Obstet Invest. 1998;45(1):62-5.
  • 68 Kobayashi Y, Itoh MT, Kondo H, Okuma Y, Sato S, Kanishi Y, et al. Melatonin binding sites in estrogen receptor-positive cells derived from human endometrial cancer. J Pineal Res. 2003;35(2):71-4.
  • 69 Park DH, Kripke DF, Louis GJ, Elliott JA, Klauber MR, Rex KM, et al. Self-reported sleep latency in postmenopausal women. J Korean Med Sci. 2007;22(6):1007-14.
  • 70 Srinivasan V, Lauterbach EC, Ho KY, Acuña-Castroviejo D, Zakaria R, Brzezinski A. Melatonin in antinociception: its therapeutic applications. Curr Neuropharmacol. 2012;10(2):167-78.
  • 71 de Zanette SA, Vercelino R, Laste G, Rozisky JR, Schwertner A, Machado CB, et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacol Toxicol. 2014;15:40.
  • 72 Danilov A, Kurganova J. Melatonin in Chronic Pain Syndromes. Pain Ther. 2016;5(1):1-17.
  • 73 Prior JC. Progesterone or progestin as menopausal ovarian hormone therapy: recent physiology-based clinical evidence. Curr Opin Endocrinol Diabetes Obes. 2015;22(6):495-501.
  • 74 Sarrel PM. Hormone replacement therapy in the menopause. Int J Fertil Womens Med. 1996;42(2):78-84.
  • 75 Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug Insight: the use of melatonergic agonists for the treatment of insomnia-focus on ramelteon. Nature Clin Pract Neurol. 2007;3(4):221-8.
  • 76 Mehta N, Shafi F, Bhat A. Unique Aspects of Sleep in Women. Mo Med. 2015;112(6):430-4.
  • 77 Pandi-Perumal SR, Srinivasan V, Spence DW, Cardinali DP. Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs. 2007;21(12):995-1018.
  • 78 Srinivasan V, Spence WD, Pandi-Perumal SR, Zakharia R, Bhatnagar KP, Brzezinski A. Melatonin and human reproduction: shedding light on the darkness hormone. Gynecol Endocrinol. 2009;25(12):779-85.
  • 79 Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336(3):186-95.
  • 80 Shochat T, Haimov I, Lavie P. Melatonin--the key to the gate of sleep. Ann Med. 1998;30(1):109-14.
  • 81 Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. Sleep. 1995;18(7):598-603.
  • 82 Toffol E, Kalleinen N, Haukka J, Vakkuri O, Partonen T, Polo-Kantola P. Melatonin in perimenopausal and postmenopausal women: associations with mood, sleep, climacteric symptoms, and quality of life. Menopause. 2014;21(5):493-500.
  • 83 Vakkuri O, Kivelä A, Leppäluoto J, Valtonen M, Kauppila A. Decrease in melatonin precedes follicle-stimulating hormone increase during perimenopause. Eur J Endocrinol. 1996;135(2):188-92.
  • 84 Pandi-Perumal SR, Seils LK, Kayumov L, Ralph MR, Lowe A, Moller H, et al. Senescence, sleep, and circadian rhythms. Ageing Res Rev. 2002;1(3):559-604.
  • 85 Bellipanni G, Bianchi P, Pierpaoli W, Bulian D, Ilyia E. Effects of melatonin in perimenopausal and menopausal women: a randomized and placebo controlled study. Exp Gerontol. 2001;36(2):297-310.
  • 86 Bellipanni G, Di Marzo F, Blasi F, Di Marzo A. Effects of melatonin in perimenopausal and menopausal women: our personal experience. Ann N Y Acad Sci. 2005;1057:393-402.
  • 87 Amstrup AK, Sikjaer T, Mosekilde L, Rejnmark L. The effect of melatonin treatment on postural stability, muscle strength, and quality of life and sleep in postmenopausal women: a randomized controlled trial. Nutr J. 2015;14:102.
  • 88 Kostoglou-Athanassiou I. Therapeutic applications of melatonin. Ther Adv Endocrinol Metab. 2013;4(1):13-24.
  • 89 Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF 3rd, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA. 1997;278(24):2170-7.
  • 90 Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res. 2007;16(4):372-80.
  • 91 Lemoine P, Zisapel N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. Expert Opin Pharmacother. 2012;13(6):895-905.
  • 92 Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48(2):301-10.
  • 93 Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009;15(1):32-51.
  • 94 Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, et al. Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009;26(6):613-26.
  • 95 Mayer G, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep. 2009;32(3):351-60.
  • 96 Richardson GS, Zammit G, Wang-Weigand S, Zhang J. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. J Clin Psychiatry. 2009;70(4):467-76.
  • 97 Hardeland R, Poeggeler B, Srinivasan V, Trakht I, Pandi-Perumal SR, Cardinali DP. Melatonergic drugs in clinical practice. Arzneimittelforschung. 2008;58(1):1-10.
  • 98 Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306(3):954-64.
  • 99 Srinivasan V, Brzezinski A, Pandi-Perumal SR, Spence DW, Cardinali DP, Brown GM. Melatonin agonists in primary insomnia and depression-associated insomnia: are they superior to sedative-hypnotics? Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):913-23.
  • 100 Srinivasan V, De Berardis D, Shillcutt SD, Brzezinski A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin Investig Drugs. 2012;21(10):1503-22.
  • 101 Hardeland R. Agomelatine and the risk of hepatotoxicity. J Symptoms Signs. 2014;3(5):341-6.
  • 102 Zlotos DP, Jockers R, Cecon E, Rivara S, Witt-Enderby PA. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential. J Med Chem. 2014;57(8):3161-85.
  • 103 Forsyth CB, Voigt RM, Burgess HJ, Swanson GR, Keshavarzian A. Circadian rhythms, alcohol and gut interactions. Alcohol. 2015;49(4):389-98.
  • 104 Skene D, Bojkowski C, Arendt J. Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans. Br J Clin Pharmacol. 1994;37(2):181-6.
  • 105 Herxheimer A, Petrie KJ. Melatonin for preventing and treating jet lag. Cochrane Database Syst Rev. 2001;(1):CD001520.
  • 106 Arushanian ÉB, Naumov SS. [Anti-inflammatory potential of melatonin]. Klin Med (Mosk). 2013;91(7):18-22.
  • 107 Cardinali DP, Hardeland R. Inflammaging, Metabolic Syndrome and Melatonin: A Call for Treatment Studies. Neuroendocrinology. 2016 May 11. [Epub ahead of print].